Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Studies in rodents have implicated various cytokines as paracrine mediators of increased osteoclastogenesis during estrogen deficiency, but increases in RANKL, the final effector of osteoclastogenesis, have not been demonstrated. Thus, we isolated bone marrow mononuclear cells expressing RANKL on their surfaces by two-color flow cytometry using FITC-conjugated osteoprotegerin-Fc (OPG-Fc-FITC) as a probe. The cells were characterized as preosteoblastic marrow stromal cells (MSCs), T lymphocytes, or B lymphocytes by using Ab's against bone alkaline phosphatase (BAP), CD3, and CD20, respectively, in 12 premenopausal women (Group A), 12 early postmenopausal women (Group B), and 12 age-matched, estrogen-treated postmenopausal women (Group C). Fluorescence intensity of OPG-Fc-FITC, an index of the surface concentration of RANKL per cell, was increased in Group B over Groups A and C by two- to threefold for MSCs, T cells, B cells, and total RANKL-expressing cells. Moreover, in the merged groups, RANKL expression per cell correlated directly with the bone resorption markers, serum C-terminal telopeptide of type I collagen and urine N-telopeptide of type I collagen, in all three cell types and inversely with serum 17beta-estradiol for total RANKL-expressing cells. The data suggest that upregulation of RANKL on bone marrow cells is an important determinant of increased bone resorption induced by estrogen deficiency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, estrogen deficiency is associated with an expansion of RANKL-and TNF-expressing T cells and B cells (27,28,30,31).”
From Sex steroid deficiency-associated bone loss is microbiota dependent and prevented by probiotics (2016) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“RANKL levels were increased on the surface of bone marrow cells from early postmenopausal women who are estrogen deficient”
From Pathogenesis of osteoporosis: concepts, conflicts, and prospects (2005) · cites this paper as [48]
In the citing paper
“Moreover, estrogen stimulates these bone cells to produce osteoprotegerin (OPG), a decoy receptor of RANK in osteoclast, thus inhibiting osteoclastogenesis [19, 155–159].”
From Biology of Bone Tissue: Structure, Function, and Factors That Influence Bone Cells (2015) · cites this paper as [157]
In the citing paper
“In humans, estrogen deficiency is associated with increased RANKL expression by bone marrow osteoblastic, T and B cells, whereas estrogen treatment reversed this increase ( 76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
In the citing paper
“flow cytometry studies conducted with bone marrow aspirates from postmenopausal subjects showed that saturating levels of OPG did not reduce the ability of anti-TRAIL antibodies to recognize TRAIL-positive cells (76).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [76]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“The expression of RANKL by T cells may be related, in part, to their function as immunoregulators, because targeted disruption of the RANKL gene results in mice lacking lymph nodes and with defective T and B lymphocyte differentiation (45).”
BackgroundSelf-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
Smith, E. P., Boyd, J., Frank, G. R., Takahashi, H., Cohen, R. M., Specker, B., Williams, T. C., Lubahn, D. B., & Korach, K. S. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410203311604 · Cited by 2,471 · cited 1×
“For example, ERα knockout mice have short limbs and mild osteopenia (31), whereas a young adult male with homozygous null mutations of ERα had elongated limbs and a greater degree of osteopenia (32).”
BackgroundSuda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,336
Estrogen Receptor Null Mice: What Have We Learned and Where Will They Lead Us?
Couse, J. F., & Korach, K. S. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0370 · Cited by 2,045
Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., et al. (1999) · Nature · doi:10.1038/46303 · Cited by 1,856 · cited 1×
“In an experimental mouse model of inflammatory arthritis, activated T lymphocytes expressing RANKL were shown to regulate the associated periarticular bone loss and joint destruction (46).”
BackgroundSelf-citationSex Steroids and the Construction and Conservation of the Adult Skeleton
Riggs, B. L., Khosla, S., & Melton, L. J. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.3.0465 · Cited by 1,846
Self-citation
Research works printed but not linked: 8
- 10.1210/jc.87.4.1443 · doi:10.1210/jc.87.4.1443 · Paper page
- 10.1210/en.142.12.5050 · doi:10.1210/en.142.12.5050 · Paper page
- 10.1210/en.140.9.4367 · doi:10.1210/en.140.9.4367 · Paper page
- 10.1210/en.142.6.2205 · doi:10.1210/en.142.6.2205 · Paper page
- 10.1210/jc.87.4.1550 · doi:10.1210/jc.87.4.1550 · Paper page
- 10.1210/en.141.12.4768 · doi:10.1210/en.141.12.4768 · Paper page
- Owen, 1988, Ciba Found. Symp., 136, 42
- 10.1002/1521-4141(200208)32:8<2246::AID-IMMU2246>3.0.CO;2-6 · DOI
Cited by
Items 401–500 of 821
Discovery of Potential Biomarkers for Postmenopausal Osteoporosis Based on Untargeted GC/LC-MS
Kou, J., Chunyang, H., Cui, L., Zhang, Z., Wang, W., Tan, L., Liu, D., Zheng, W., Gu, W., & Xia, N. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.849076 · Cited by 26
“org 6 (RANKL) will be overexpressed with estrogen deficiency, which is also a reason for the increase in bone resorption to achieve OP (32).”
BackgroundWang, Z., Wu, J., Li, L., Wang, K., Wu, X., Chen, H., Shi, J., Zhou, C., Zhang, W., Hang, K., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.07.022 · Cited by 26
OPG/RANKL: Implication et cible thérapeutique dans l’ostéoporose
Marie, P. J., & Halbout, P. (2008) · médecine/sciences · doi:10.1051/medsci/2008241105 · Cited by 38
Autophagy: A Promising Target for Age-related Osteoporosis
Wang, T., He, H., Liu, S., Jia, C., Fan, Z., Zhong, C., Yu, J., Liu, H., & He, C. (2018) · Current Drug Targets · doi:10.2174/1389450119666180626120852 · Cited by 25
Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Osteoporosis
Vegni, F. E., Corradini, C., & Privitera, G. (2004) · New England Journal of Medicine · doi:10.1056/nejm200401083500219 · Cited by 22
Dai, G.-C., Wang, H., Ming, Z., Lu, P., Li, Y., Gao, Y., Shi, L., Cheng, Z., Liu, X., & Rui, Y. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102215 · Cited by 24
Wei, Q., Huang, L., Chen, X.-H., Wang, H., Sun, W.-S., Huo, S.-C., Li, Z.-Q., & Deng, W. (2014) · PubMed Central · Cited by 23
Rattazzi, M., Faggin, E., Buso, R., Virgilio, R. D., Puato, M., Plebani, M., Zaninotto, M., Palmosi, T., Bertacco, E., Fadini, G. P., et al. (2015) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12163 · Cited by 23
“In particular, increased RANKL expression in T cells has been reported in patients with bone disorders [10,11] and clinical atherosclerotic disease [9].”
BackgroundRole of the immune system in postmenopausal bone loss
Weitzmann, M. N., & Pacifici, R. (2005) · Current Osteoporosis Reports · doi:10.1007/s11914-005-0016-8 · Cited by 22
“While the upregulation of IL-1 after ovariectomy in humans and mice has long been recognized [1], and suppression of IL-1 shown to be partially effective in preventing ovariectomy induced bone loss in mice and rats [ 2 ,3,36], the mechanism of IL-1 action is still not well understood.”
BackgroundInfluentialImmunology of Gut-Bone Signaling
Collins, F. L., Schepper, J. D., Rios‐Arce, N. D., Steury, M. D., Kang, H. J., Mallin, H., Schoenherr, D. T., Camfield, G., Chishti, S., McCabe, L. R., et al. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66653-2_5 · Cited by 24
Estrogen Deficiency and Osteoporosis
Okman, T. K. (2015) · InTech eBooks · doi:10.5772/59407 · Cited by 29
“This situation is important in the occurance of postmenopausal bone loss [34,35].”
BackgroundNew biochemical markers of bone turnover
Garnero, P. (2008) · IBMS BoneKEy · doi:10.1138/20080302 · Cited by 28
“(40) who analyzed RANKL expression by bone marrow mononuclear cells and T and B lymphocytes from premenopausal women, untreated postmenopausal women and postmenopausal women treated with estrogen.”
BackgroundLIGHT/TNFSF14 regulates estrogen deficiency‐induced bone loss
Brunetti, G., Storlino, G., Oranger, A., Colaianni, G., Faienza, M. F., Ingravallo, G., Comite, M. D., Reseland, J. E., Celi, M., Tarantino, U., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5385 · Cited by 21
“Additionally, in postmenopausal osteoporosis, high RANKL levels in marrow stromal cells and lymphocytes were associated with the enhanced markers of bone resorption and with the circulating estrogen concentration [45].”
BackgroundOsteoporosis: From osteoscience to neuroscience and beyond
Kwan, P. (2015) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2015.02.001 · Cited by 21
Harding, G., Mak, Y. T., Evans, B. A. J., Cheung, J., MacDonald, D., & Hampson, G. (2006) · Cytokine · doi:10.1016/j.cyto.2006.10.012 · Cited by 23
Dündar, Ü., Kavuncu, V., Çiftçi, İ. H., Evcik, D., Solak, Ö., & Çakır, T. (2009) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-009-0055-9 · Cited by 23
“In bone marrow, RANKL is expressed on the surfaces of the osteoblast lineage, T lymphocytes, and B lymphocytes [8, 9].”
BackgroundBaeg, M. K., Yoon, S. K., Ko, S.-H., Han, K.-D., Choi, H. J., Bae, S. H., Choi, J. Y., & Choi, M. (2016) · Hepatology International · doi:10.1007/s12072-015-9672-7 · Cited by 20
Tumour necrosis factor blockade and the risk of osteoporosis: back to the future
Sambrook, P. N. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2277 · Cited by 20
“RANK and its decoy receptor OPG are key regulators of osteoclastic bone resorption in vitro and in vivo [4,5].”
BackgroundSmuthkochorn, S., Palomo, J. M., Hans, M. G., Jones, C. S., & Palomo, L. (2017) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2016.11.027 · Cited by 22
“Our finding that there are baseline differences in RANKL and OPN concentrations in GCF are consistent with reports that noted similar serum RANKL and OPN profiles in postmenopausal women.(17-19) On 1 hand, this is not surprising since GCF is a filtrate of serum; however, our findings indicate that the biomarker respon…”
ResultThe role of estrogens in osteosarcopenia: from biology to potential dual therapeutic effects
Mandelli, A., Tacconi, E., Levinger, I., Duque, G., & Hayes, A. (2021) · Climacteric · doi:10.1080/13697137.2021.1965118 · Cited by 23
“strated that postmenopausal women show a greater production of RANKL, which in turn contributes to the increased bone resorption by osteoclasts [38] (Figure 2).”
BackgroundBone remodeling humoral networks and smart biomaterial technology for osteoporosis
Fini, M., Carpi, A., Borsari, V., Tschon, M., Nicolini, A., Sartori, M., Mechanick, J., & Giardino, R. (2010) · Frontiers in Bioscience-Scholar · doi:10.2741/s79 · Cited by 22
“(72) demonstrated that RANKL expression is significantly higher in post-menopausal women, compared with premenopausal women and post-menopausal women treated with estrogen.”
BackgroundCao, H., Lei, S., Deng, H., & Wang, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042755 · Cited by 19
“In the present study we selected circulating monocytes as our target cells because circulating monocytes serve as progenitors of osteoclasts [21-23], and secrete osteoclastogenic cytokines, such as IL-1, IL-6, and TNF- [24-26].”
BackgroundVitamin E suppresses ex vivo osteoclastogenesis in ovariectomized rats
Johnson, S. A., Feresin, R. G., Soung, D. Y., Elam, M. L., & Arjmandi, B. H. (2016) · Food & Function · doi:10.1039/c5fo01066g · Cited by 22
The interconnected role of chemokines and estrogen in bone metabolism
Xu, Y., Chu, N., Qiu, X., Gober, H.-J., Li, D., & Wang, L. (2016) · BioScience Trends · doi:10.5582/bst.2016.01072 · Cited by 21
Ma, M., Luo, S., Zhou, W., Lu, L., Cai, J., Yuan, F., & Yin, F. (2017) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2016.04.038 · Cited by 20
Thouverey, C., & Caverzasio, J. (2015) · Endocrinology · doi:10.1210/en.2015-1669 · Cited by 19
Mabilleau, G., Pascaretti‐Grizon, F., Baslé, M. F., & Chappard, D. (2011) · Cytokine · doi:10.1016/j.cyto.2011.11.014 · Cited by 20
“Involvement of the RANKL/RANK pathway has been recently reported in bone disorders characterised by increased bone resorption such as post-menopausal osteoporosis [12,13], rheumatoid arthritis (RA) [14,15] and bone metastases [16,17].”
Chiba, Y., Onouchi, T., Ikeda, T., Adachi, J., Tamura, Y., & Horiuchi, T. (2009) · Gerontology · doi:10.1159/000196280 · Cited by 23
“Factors that increase RANKL mRNA expression include the proinflammatory cytokines, TNF-α, IL-1, IL-2, and prostaglandin E 2 . RANKL expression by T cells upregulates osteoclastogenesis and may contribute to bone loss when its level is increased [”
BackgroundPignolo, R. J. (2023) · Comprehensive physiology · doi:10.1002/cphy.c220012 · Cited by 56
Skeletal Effects of Inducible ERα Deletion in Osteocytes in Adult Mice
Doolittle, M. L., Saul, D., Kaur, J., Rowsey, J. L., Eckhardt, B. A., Vos, S., Grain, S., Kroupova, K., Ruan, M. M., Weivoda, M. M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4644 · Cited by 21
“4D), or Sostdc1, which have been shown to be regulated by estrogen or following ERα deletion in other studies in mice and humans,((6,32,33)) was not altered in the ERαΔOcy mice (Fig.”
BackgroundSelf-citationBrandi, M., & Cavalli, L. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s7688 · Cited by 19
“Estrogen deficiency is also associated with an increment of osteoclasts and RANKL levels.(71) This evidence led to the development of targeted molecules specifically interacting with RANK/RANKL/ OPG pathway.”
BackgroundInfluentialRole of the Osteocyte in Musculoskeletal Disease
Shimonty, A., Bonewald, L. F., & Pin, F. (2023) · Current Osteoporosis Reports · doi:10.1007/s11914-023-00788-5 · Cited by 18
“RANKL is increased in menopausal women and plays a critical role in driving bone loss that characterizes osteoporosis [39].”
BackgroundDecrease in particle‐induced osteolysis in ovariectomized mice
Nich, C., Marchadier, A., Sedel, L., Petite, H., Vidal, C., & Hamadouche, M. (2009) · Journal of Orthopaedic Research® · doi:10.1002/jor.20987 · Cited by 18
Bone Disease in Multiple Myeloma
Hjertner, Ø., Standal, T., Børset, M., Sundan, A., & Waage, A. (2006) · Medical Oncology · doi:10.1385/mo:23:4:431 · Cited by 19
The Role of Sex Steroids in the Pathogenesis of Osteoporosis
Drake, M. T., & Khosla, S. (2013) · Wiley eBooks · doi:10.1002/9781118453926.ch43 · Cited by 22
Self-citationWong‐Pack, M., Kalani, A., Hordyk, J., Ioannidis, G., Bensen, R., Bensen, W., Παπαϊωάννου, Α., Adachi, J. D., & Lau, A. N. (2016) · Journal of Osteoporosis · doi:10.1155/2016/7903128 · Cited by 17
“In postmenopausal women, increases in RANK ligand production have been associated with an increase in osteoclast activity and overall net bone resorption [18, 19].”
BackgroundZhou, X., Sun, S., Chen, Y., Liu, C., Li, D., Cheng, Q., Cheng, Q., Li, Y., Xu, K., & Ta, D. (2023) · Ultrasonics · doi:10.1016/j.ultras.2023.106973 · Cited by 18
Kamiya, N., Suzuki, H., Endo, T., Takano, M., Yano, M., Naoi, M., Kawamura, K., Imamoto, T., Takanami, M., & Ichikawa, T. (2011) · International Journal of Clinical Oncology · doi:10.1007/s10147-011-0193-7 · Cited by 17
“RANKL is a member of the TNF superfamily that is expressed by osteoblasts, bone marrow stromal cells, and activated T-cells [23, 24].”
BackgroundShoukry, A., Shalaby, S. M., Etewa, R. L., Ahmed, H. S., & Abdel-Rahman, H. M. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2391-5 · Cited by 17
“postmenopausal women who are estrogen deficient [19].”
Bone Loss Among Women Living With HIV
Weitzmann, M. N., Ofotokun, I., Titanji, K., Sharma, A., & Yin, M. T. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0336-6 · Cited by 18
Ablation of the mammalian lectin galectin‐8 induces bone defects in mice
Vinik, Y., Shatz‐Azoulay, H., Hiram‐Bab, S., Kandel, L., Gabet, Y., Rivkin, G., & Zick, Y. (2017) · The FASEB Journal · doi:10.1096/fj.201700716r · Cited by 17
“One plausible mechanism could be the elevation in RANKL expression, which occurs in estrogen deficiency (54) as well as upon gal-8 overexpression (17).”
BackgroundClinical Impact of RANK Signalling in Ovarian Cancer
Wieser, V. E., Sprung, S., Tsibulak, I., Haybaeck, J., Hackl, H., Fiegl, H., Marth, C., & Zeimet, A. G. (2019) · Cancers · doi:10.3390/cancers11060791 · Cited by 18
The role of the immune system in the physiopathology of osteoporosis.
Cagnetta, V., & Patella, V. (2012) · PubMed · Cited by 26
Genetics of Osteoporosis: Perspectives for Personalized Medicine
Li, W., Hou, S.-X., Yu, B., Jin, D., Férec, C., & Chen, J. (2010) · Personalized Medicine · doi:10.2217/pme.10.55 · Cited by 20
Magalhaes, J., Grynpas, M. D., Willett, T. L., & Glogauer, M. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1355-6 · Cited by 18
“recently suggested that the up-regulation of receptor activator for nuclear factor κ B ligand (RANKL) in bone marrow cells is a key determinant for the enhanced bone resorption induced by estrogen deficiency [33].”
BackgroundThe Molecular Biological Approach in Paleopathology
Gosman, J. H. (2011) · Wiley eBooks · doi:10.1002/9781444345940.ch5 · Cited by 20
The Role of Exercise on Fracture Reduction and Bone Strengthening
KEMMLER, W. K., & von Stengel, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814593-7.00020-7 · Cited by 28
Amer, O. E., Wani, K., Ansari, M. G. A., Alnaami, A. M., Aljohani, N., Abdi, S., Hussain, S. D., Al‐Daghri, N. M., & Alokail, M. S. (2022) · Medicina · doi:10.3390/medicina58080976 · Cited by 19
“Other studies, however, found that serum levels of OPG were age-independent and did not show differences between pre-and postmenopausal women [33].”
Regulatory cellular and molecular networks in the bone microenvironment during aging
Zhang, L., Wang, Z., Zhang, Y., Ji, R., Li, Z., Zou, J., & Gao, B. (2024) · Life Medicine · doi:10.1093/lifemedi/lnae019 · Cited by 22
Rauner, M., Stein, N., & Hofbauer, L. C. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0520-7_1 · Cited by 19
Kim, J. G., Kim, J. H., Lee, D. O., Kim, H., Kim, J. Y., Suh, C. S., Kim, S. H., & Choi, Y. M. (2008) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318133a153 · Cited by 18
Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo
Clowes, J. A., Eghbali-Fatourechi, G., McCready, L. K., Oursler, M. J., Khosla, S., & Riggs, B. L. (2008) · Osteoporosis International · doi:10.1007/s00198-008-0731-y · Cited by 16
“[11] demonstrated that E-deficient postmenopausal women had increased surface concentration of RANKL on marrow stromal cells and T and B lymphocytes.”
BackgroundMethodInfluentialSelf-citationCapozzi, A., Lello, S., & Pontecorvi, A. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2014.892067 · Cited by 20
“However, the excess of RANKL found in particular conditions like estrogen deficiency [12] or bone metastases [13], results in increased bone loss.”
BackgroundMohamed, R. H., Mohamed, R. H., & El-Shahawy, E. E. (2016) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2015.0227 · Cited by 21
“Eghbali-Fatourechi et al. (2003) reported that upregulation of RANKL in bone marrow cells can promote bone resorption, providing biological support for a functional role of RANKL in bone remodeling.”
Osteoprotegerin as a potential therapy for osteoporosis
Hamdy, N. A. T. (2006) · Current Rheumatology Reports · doi:10.1007/s11926-006-0026-2 · Cited by 17
“Endogenous RANKL expression may be suppressed by 17β-estradiol [ 30 ].”
BackgroundResultInfluentialBabür, C., Özcan, G., Çebi, D. U., Pervane, B., Özdemir, B., Yücel, A. A., Bırı, A., & Babür, C. (2012) · Journal of Dentistry · doi:10.1016/j.jdent.2012.01.013 · Cited by 19
“Some authors reported a significant increase of serum OPG levels in postmenopausal women,(6) some found serum concentrations of OPG did not differ amongst premenopausal and postmenopausal women.(38) In addition, significantly higher serum OPG levels were detected in osteoporosis patients than in control groups amongst…”
BackgroundRadzi, N. F. M., Ismail, N. A. S., & Alias, E. (2018) · Current Drug Targets · doi:10.2174/1389450119666180207092539 · Cited by 17
“The expression and levels of RANKL and OPG have been reported to be altered in osteoporosis [14, 15], rheumatoid arthritis [16-18] and peri-implant osteolysis [19-21], and this may suggest that increased osteoclast formation and activity could be responsible for the bone loss observed in those diseases.”
BackgroundSelby, P. L. (2004) · Current Osteoporosis Reports · doi:10.1007/s11914-004-0018-y · Cited by 21
Nisha, Y., Dubashi, B., Bobby, Z., Sahoo, J. P., & Kayal, S. (2021) · Supportive Care in Cancer · doi:10.1007/s00520-021-06231-8 · Cited by 16
“Estrogen increases OPG and decreases RANKL, resulting in reduced osteoclastic function and bone resorption [15].”
BackgroundDenosumab Discontinuation in Patients Treated for Low Bone Density and Osteoporosis
Zeytinoglu, M., Naaman, S., & Dickens, L. T. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.03.004 · Cited by 17
Effects of Estrogens on Osteoimmunology: A Role in Bone Metastasis
Marie, J. C., & Bonnelye, E. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.899104 · Cited by 18
“Interestingly, in post-menopausal women, a switch from OPG to RANK-L production is observed in B cells emphasizing bone loss (96, 97).”
BackgroundMonteiro, A. C., Garcia, D. D., Rocher, B. D., Fontão, A. P. G. A., Nogueira, L. P., Fidalgo, G., Colaço, M. V., & Bonomo, A. C. (2023) · Bone · doi:10.1016/j.bone.2023.116932 · Cited by 18
Introduction to Bone Development, Remodelling and Repair
Gruber, R., Pietschmann, P., & Peterlik, M. (2008) · Medical radiology · doi:10.1007/978-3-540-68604-0_1 · Cited by 17
Molecular Mechanism of Thiazolidinedione-Mediated Inhibitory Effects on Osteoclastogenesis
Zhao, D., Shi, Z., Warriner, A. H., Qiao, P., Hong, H., Wang, Y., & Feng, X. (2014) · PLoS ONE · doi:10.1371/journal.pone.0102706 · Cited by 16
“So, how can our findings explain the clinical observation? To address this issue, we would like to highlight following important observations: a) TZDs inhibit osteoblast differentiation and bone formation [19–21]; b) TZDs induce bone loss in ovariectomized rats but not in intact rats [56]; c) TZD-induced bone loss is…”
BackgroundRetractedLow bone-mineral density in patients with HIV: pathogenesis and clinical significance
Yin, M. T., & Shane, E. J. (2006) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/med.0b013e3280109b6c · Cited by 17
Sze, S. C. W., Ip, C. W., Ng, T. B., Zhang, K. Y., Zhang, Z., Cheung, H. P., Cheng, C. L. Y., & Tong, Y. (2012) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2012.01.006 · Cited by 15
Zulfiqar, Z., Huang, S., & Shi, Y. (2025) · Animal nutrition · doi:10.1016/j.aninu.2025.05.002 · Cited by 19
“Estrogen reduces the expression of RANKL in CD 3 + T cells and CD 20 + B cells (Eghbali-Fatourechi et al., 2003), while increasing OPG synthesis in osteoblastic cells (Khosla et al., 2012).”
Sui, K., Tveter, K. M., Bawagan, F. G., Buckendahl, P., Martinez, S. A., Jaffri, Z. H., MacDonell, A. T., Wu, Y., Duran, R. M., Shapses, S. A., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.900667 · Cited by 20
“Osteoclastogenesis and bone resorption occurs when receptor activator of nuclear factor κB (RANK) on osteoclast cell membranes interacts with membrane-associated RANKLigand (RANKL) expressed on osteoblasts, osteocytes, and B and T lymphocytes (Eghbali-Fatourechi et al., 2003; Taxel et al., 2008).”
BackgroundMornar, M., Novak, A., Božić, J., Vrdoljak, J., Kumrić, M., Vilović, T., Rakovic, I., Kurir, T. T., Martinović, D., Urlić, H., et al. (2023) · Quality of Life Research · doi:10.1007/s11136-023-03542-7 · Cited by 15
Dinh, T. D., Higuchi, Y., Kawakami, S., Yamashita, F., & Hashida, M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0366-0 · Cited by 14
“In RA, the synergistic relationship between TNF- and RANKL serves to enhance the osteoclastogenic properties of both proinflammatory cytokines (5,6).”
BackgroundTodenhöfer, T., Hennenlotter, J., Schmiedel, B. J., Hohneder, A., Grimm, S., Kühs, U., Salih, H. R., Bühring, H., Fehm, T. N., Gakis, G., et al. (2012) · The Prostate · doi:10.1002/pros.22551 · Cited by 14
“, [31] who investigated expression of membrane bound RANKL in BM of premenopausal and postmenopausal women and observed a proportion of RANKLexpressing cells up to 6%, we detected <0.”
BackgroundPulsed low-dose RANKL as a potential therapeutic for postmenopausal osteoporosis
Cline-Smith, A., Gibbs, J., Shashkova, E. V., Buchwald, Z. S., & Aurora, R. (2016) · JCI Insight · doi:10.1172/jci.insight.88839 · Cited by 15
A correlative studies between osteoporosis and blood cell composition
Ye, X., Jiang, H., Wang, Y., Ji, Y., & Jiang, X. (2020) · Medicine · doi:10.1097/md.0000000000020864 · Cited by 14
Targeting Drug Delivery in the Elderly: Are Nanoparticles an Option for Treating Osteoporosis?
Thurner, G. C., Haybaeck, J., & Debbage, P. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168932 · Cited by 15
“Estrogen suppresses osteoblasts ́RANKL production [76] and increases OPG production [77], and”
BackgroundThe Microbiota-Bone-Allergy Interplay
Sirufo, M. M., Pietro, F. D., Catalogna, A., Ginaldi, L., & Martinis, M. D. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19010282 · Cited by 14
Bonnet, N., Douni, E. K., Lopreno, G. P., Besse, M., Biver, E., & Ferrari, S. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4307 · Cited by 15
“increasing bone resorption and removing bone from the trabecular, endocortical, and intracortical compartments.((3,4)) To coun-”
BackgroundSerum Osteoprotegerin, RANKL, and Dkk-1 Levels in Adults with Langerhans Cell Histiocytosis
Makras, P., Pοlyzos, S. A., Anastasilakis, A. D., Terpos, E., Kanakis, G., Schini, M., Παπαθεοδώρου, Α., & Kaltsas, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2962 · Cited by 14
“In addition, serum RANKL reflects only a small part of its total production because the majority is cell-bound and can be only assessed in vivo by flow cytometry after bone biopsy (14).”
BackgroundPathophysiology and Pathomorphology of Osteoporosis
Beil, F. T., Seitz, S. A., Priemel, M., Barvencik, F., von Domarus, C., Rueger, J. M., Amling, M., & Pogoda, P. (2008) · European Journal of Trauma and Emergency Surgery · doi:10.1007/s00068-008-8201-y · Cited by 16
“The interaction from RANKL/ RANK is of central importance for both the differentiation and the functional activation of osteoclasts and, therefore, has a mechanistic key role in the process of bone loss syndromes which are based on an increased resorption [39, 40].”
Ahmed, M. F. E. M., Elsayed, A. K., Chen, H., Zhao, R., Yusuf, M. S., Zuo, Q., Zhang, Y., & Li, B. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7414 · Cited by 16
“deficiency in humans results in increased bone resorption (93).”
BackgroundRufato, F. C. T., de Sousa, L. G., Scalize, P. H., Gimenes, R., Regalo, I. H., Rosa, A. L., Beloti, M. M., Oliveira, F. S., Bombonato‐Prado, K. F., Regalo, S. C. H., et al. (2021) · Clinical Oral Investigations · doi:10.1007/s00784-021-04089-y · Cited by 13
“The ratio Rankl/Opg was significantly decreased in the group OVX + P(VDF) when compared to OVX + P(VDF) + L and OVX + PTFE + L groups (p 0.05).”
BackgroundInfluentialRANKL elevation activates the NIK/NF-κB pathway, inducing obesity in ovariectomized mice
Mori, K., Mizokami, A., Sano, T., Mukai, S., Hiura, F., Ayukawa, Y., Koyano, K., Kanematsu, T., & Jimi, E. (2022) · Journal of Endocrinology · doi:10.1530/joe-21-0424 · Cited by 14
Li, F., Li, H., Zhai, Q., Li, F., Wu, T., Sha, X., Zhang, B., Yang, W., Lu, Z., & Tao, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.205 · Cited by 13
Pοlyzos, S. A., & Goulas, A. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.110379 · Cited by 13
Weitzmann, M. N. (2017) · Molecular and integrative toxicology · doi:10.1007/978-3-319-56192-9_12 · Cited by 14
Interactions between the immune system and bone
D’Amelio, P. (2011) · World Journal of Orthopedics · doi:10.5312/wjo.v2.i3.25 · Cited by 13
The impact of sex steroids on osteonecrosis of the jaw
Kim, R., Kim, S. W., Kim, H., & Ku, S. (2022) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2022.05.003 · Cited by 18
“Studies have shown that estrogen suppresses RANKL production and increases osteoprotegerin production, which inhibits osteoclast activation [25,28,29].”
BackgroundBülow, J. M., Renz, N., Haffner‐Luntzer, M., Fischer, V., Schoppa, A., Tuckermann, J. P., Köhl, J., Huber-Lang, M. S., & Ignatius, A. A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1016057 · Cited by 13
Ruiz-Lozano, R., Calvo‐Gallego, J. L., Pivonka, P., McDonald, M. M., & Martínez‐Reina, J. (2024) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-024-01846-2 · Cited by 15
“More precisely, oestrogen deficiency produces an enhanced RANKL expression by stromal cells and lymphocytes (Eghbali-Fatourechi et al. 2003) and increases the responsiveness of osteoclasts to RANKL (Shevde et al. 2000) and those effects have been taken into account here through a production of…”
InfluentialDoes radiographic emphysema correlate with low bone mineral density?
Bon, J. M. (2012) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32834f8194 · Cited by 12
“More recent studies have shown that the receptor activator of nuclear factor kb (RANK), a member of the TNF-a superfamily present on osteoblasts and T-cells, its ligand (RANKL) and the decoy receptor osteoprotegerin are key regulators of osteoclastic bone resorption [31,55,56].”
BackgroundThảo, N. P., Luyen, B. T. T., Lee, S. H., Jang, H. D., Kiệm, P. V., Minh, C. V., & Kim, Y. H. (2015) · Medicinal Chemistry Research · doi:10.1007/s00044-015-1395-8 · Cited by 14
Belaya, Z. E., & Rozhinskaya, L. Y. (2011) · Osteoporosis and Bone Diseases · doi:10.14341/osteo2011223-26 · Cited by 12
Protein Markers in Osteoporosis
Porcelli, T., Pezzaioli, L. C., Delbarba, A., Maffezzoni, F., Cappelli, C., & Ferlin, A. (2020) · Protein and Peptide Letters · doi:10.2174/1871530320666200425204634 · Cited by 12
The regulatory roles of long noncoding RNAs in osteoporosis.
Zhao, W., Wang, G., Zhou, C., & Zhao, Q. (2020) · PubMed Central · Cited by 15
Rossini, A., Frigerio, S., Dozio, E., Trevisan, R., Perseghin, G., & Corbetta, S. (2020) · International Journal of Endocrinology · doi:10.1155/2020/1809150 · Cited by 12
“Elevated RANKL activity has been demonstrated in various conditions of reduced bone mass [17].”
BackgroundSmoking-Induced Oxidative Stress in Bone: The Effects on Bone Turnover
Kohler, J. B., Junqueira, J. J. M., da Silva, T. C. M., Filho, M. A. G. P., Tiberio, I. D. F. L. C., Lopes, F. D. T. Q. S., & Barbosa, A. P. (2021) · Journal of Orthopedics and Orthopedic Surgery · doi:10.29245/2767-5130/2021/2.1138 · Cited by 12
Soliman, T. M., Ali, Z., Zayed, M., Sabry, D., & AbuBakr, N. (2022) · Dental and Medical Problems · doi:10.17219/dmp/139200 · Cited by 15
Emerging antiresorptive medications and their potential implications for dental surgeries
Aminoshariae, A., Donaldson, M., Horan, M., Mackey, S. A., Kulild, J., & Baur, D. A. (2022) · The Journal of the American Dental Association · doi:10.1016/j.adaj.2021.12.008 · Cited by 14
Roux, S., & Brown, J. P. (2009) · Current Rheumatology Reviews · doi:10.2174/157339709788298428 · Cited by 16
“Moreover, RANKL expression per cell was shown to be directly correlated to bone resorption markers, and inversely related to with serum estrogen levels [76].”
BackgroundTsourdi, E. A., Salbach‐Hirsch, J., Rauner, M., Rachner, T. D., Möller, S., Schnabelrauch, M., Scharnweber, D., & Hofbauer, L. C. (2014) · Journal of Bioactive and Compatible Polymers · doi:10.1177/0883911514546983 · Cited by 13
Hiyama, S., Yokoi, M., Akagi, Y., Kadoyama, Y., Nakamori, K., Tsuga, K., Uchida, T., & Terayama, R. (2019) · Journal of Molecular Histology · doi:10.1007/s10735-019-09835-x · Cited by 12
Metadata
- Authors
- Eghbali-Fatourechi, G., Khosla, S., Sanyal, A., Boyle, W. J., Lacey, D. L., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Corresponding author
- Riggs, B. Lawrence
- Venue
- Journal of Clinical Investigation
- Published
- 2003-04-15
- Volume
- 111
- Issue
- 8
- Pages
- 1221-1230
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC152939
- OpenAlex
- W4254761345
- Cited by
- 825
- References
- 44
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 28 · 2023: 25 · 2022: 34 · 2021: 36 · 2020: 41 · 2019: 30 · 2018: 39 · 2017: 39 · 2016: 33 · 2015: 45 · 2014: 31 · 2013: 42 · 2012: 52
- FWCI
- 11.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- National Institutes of Health (M01-RR00 585, AG 04875, RR-00585)
- U.S. Public Health Service (AG-04875)
- National Institute on Aging (P01-AG04875, P01AG004875)
- National Center for Research Resources (M01-RR00 585, M01RR000585)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Keywords
- RANK ligand, bone resorption, postmenopausal osteoporosis, estrogen deficiency, osteoclastogenesis, mesenchymal stem cells, T cells, B cells, osteoprotegerin, estradiol, bone turnover markers, paracrine signaling
- MeSH terms
- Adult, Bone Resorption, Carrier Proteins, Female, Flow Cytometry, Glycoproteins, Humans, Membrane Glycoproteins, Middle Aged, Tumor Necrosis Factor-alpha, Osteoporosis, Postmenopausal, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Apoptosis Regulatory Proteins, TNF-Related Apoptosis-Inducing Ligand, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.